Ultragenyx Pharmaceutical Inc. (RARE) Insider Trading

Last 12 months

Insiders sold $3.81M and bought nothing on the open market.

35% of the selling was scheduled in advance under 10b5-1 plans. President & CEO Emil D Kakkis sold $1.24M on Mar 2 outside a plan. The last open-market buy by an executive or director was in Sep 2019.

Net open-market

−$3.81M

0 buys · 25 sales

Under a 10b5-1 plan

35%

of the value sold

Insiders who bought / sold

0 / 9

executives and directors

Last open-market buy

Sep 2019

Sep 11, 2019

Get an email when RARE's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 15	Howard Horn Chief Financial Officer	SoldNo plan	7,066	$15.27	$108k	7.3%	Form 4
Sep 15	Theodore Alan Huizenga SVP, Chief Accounting Officer	Sold10b5-1 plan	1,283	$13.57	$17k	1.9%	Form 4
Sep 3	Theodore Alan Huizenga SVP, Chief Accounting Officer	SoldNo plan	161	$13.99	$2k	0.2%	Form 4
Aug 3	Karah Herdman Parschauer EVP and Chief Legal Officer	Sold10b5-1 plan	1,900	$24.92	$47k	2.0%	Form 4
Aug 3	Howard Horn Chief Financial Officer	Sold10b5-1 plan	4,696	$24.92	$117k	4.6%	Form 4
Jul 1	Howard Horn Chief Financial Officer	Sold10b5-1 plan	4,698	$33.13	$156k	4.4%	Form 4
Jun 15	Corazon (corsee) D. Sanders Director	SoldNo plan	2,000	$25.05	$50k	8.7%	Form 4
Jun 15	Karah Herdman Parschauer EVP and Chief Legal Officer	Sold10b5-1 plan	1,899	$24.62	$47k	2.0%	Form 4
Jun 1	Howard Horn Chief Financial Officer	Sold10b5-1 plan	4,653	$23.77	$111k	4.2%	Form 4
May 18	Shehnaaz Suliman Director	Sold10b5-1 plan	5,740	$25.12	$144k	17%	Form 4
May 5	Eric Crombez EVP and Chief Medical Officer	SoldNo plan	344	$24.96	$9k	0.3%	Form 4
May 1	Howard Horn Chief Financial Officer	Sold10b5-1 plan	4,683	$24.90	$117k	4.1%	Form 4
Apr 1	Howard Horn Chief Financial Officer	Sold10b5-1 plan	4,683	$20.97	$98k	5.5%	Form 4
Mar 6 – 10	Karah Herdman Parschauer EVP and Chief Legal Officer	SoldNo plan 2 parts	9,526	$21.87 average	$208k	12%	Form 4
Mar 2 – 3	Howard Horn Chief Financial Officer	Sold10b5-1 plan 3 parts	10,044	$22.65 average	$228k	11%	Form 4
Mar 2	John Richard Pinion See Remarks	SoldNo plan	10,029	$22.80	$229k	8.4%	Form 4
Mar 2	Erik Harris EVP & Chief Commercial Officer	SoldNo plan	10,539	$22.80	$240k	11%	Form 4
Mar 2	Emil D Kakkis President & CEO	SoldNo plan	54,404	$22.80	$1.24M	1.9%	Form 4
Mar 2	Karah Herdman Parschauer EVP and Chief Legal Officer	SoldNo plan	8,135	$22.80	$185k	9.6%	Form 4
Mar 2	Theodore Alan Huizenga SVP, Chief Accounting Officer	SoldNo plan	1,632	$22.80	$37k	3.2%	Form 4
Mar 2	Eric Crombez EVP and Chief Medical Officer	SoldNo plan	7,029	$22.80	$160k	8.4%	Form 4
Feb 2	Howard Horn Chief Financial Officer	Sold10b5-1 plan	3,061	$23.56	$72k	3.3%	Form 4
Jan 2	Howard Horn Chief Financial Officer	Sold10b5-1 plan	3,150	$22.84	$72k	3.3%	Form 4
Dec 29, 2025	Theodore Alan Huizenga SVP, Chief Accounting Officer	SoldNo plan	85	$34.38	$3k	0.2%	Form 4
Dec 10, 2025	Howard Horn Chief Financial Officer	Sold10b5-1 plan	3,081	$36.38	$112k	3.1%	Form 4
Oct 13, 2025	Howard Horn Chief Financial Officer	SoldNo plan	7,942	$31.51	$250k	7.5%	Form 4
Sep 18, 2025	Theodore Alan Huizenga SVP, Chief Accounting Officer	SoldNo plan	64	$29.17	$2k	0.1%	Form 4
Sep 12, 2025	Karah Herdman Parschauer EVP and Chief Legal Officer	SoldNo plan	2,450	$31.17	$76k	3.2%	Form 4
Sep 5, 2025	Theodore Alan Huizenga SVP, Chief Accounting Officer	SoldNo plan	84	$31.39	$3k	0.2%	Form 4
Jun 20, 2025	Corazon (corsee) D. Sanders Director	Sold10b5-1 plan	2,405	$37.39	$90k	14%	Form 4
Apr 21, 2025 – May 5, 2025	Eric Crombez EVP and Chief Medical Officer	SoldNo plan 2 parts	762	$37.93 average	$29k	1.1%	Form 4
Mar 6, 2025	Howard Horn Chief Financial Officer	SoldNo plan	1,785	$40.40	$72k	1.7%	Form 4
Mar 3, 2025	Thomas Richard Kassberg CBO & EVP	SoldNo plan	6,028	$42.10	$254k	2.2%	Form 4
Mar 3, 2025	Karah Herdman Parschauer EVP and Chief Legal Officer	SoldNo plan	12,846	$42.10	$541k	15%	Form 4
Mar 3, 2025	Eric Crombez EVP and Chief Medical Officer	SoldNo plan	8,945	$42.10	$377k	11%	Form 4
Mar 3, 2025	John Richard Pinion See Remarks	SoldNo plan	14,439	$42.10	$608k	12%	Form 4
Feb 28, 2025 – Mar 3, 2025	Emil D Kakkis President & CEO	Sold10b5-1 plan 2 parts	98,434	$42.20 average	$4.15M	3.4%	Form 4
Mar 3, 2025	Erik Harris EVP & Chief Commercial Officer	SoldNo plan	15,103	$42.10	$636k	15%	Form 4
Mar 3, 2025	Theodore Alan Huizenga SVP, Chief Accounting Officer	SoldNo plan	967	$42.10	$41k	1.9%	Form 4
Feb 27, 2025	Karah Herdman Parschauer EVP and Chief Legal Officer	SoldNo plan 2 parts	2,990	$42.88 average	$128k	4.1%	Form 4

Oct 15No plan
Howard Horn
Chief Financial Officer · sold 7,066 at $15.27
$108k
7.3% of stake
Sep 1510b5-1 plan
Theodore Alan Huizenga
SVP, Chief Accounting Officer · sold 1,283 at $13.57
$17k
1.9% of stake
Sep 3No plan
Theodore Alan Huizenga
SVP, Chief Accounting Officer · sold 161 at $13.99
$2k
0.2% of stake
Aug 310b5-1 plan
Karah Herdman Parschauer
EVP and Chief Legal Officer · sold 1,900 at $24.92
$47k
2.0% of stake
Aug 310b5-1 plan
Howard Horn
Chief Financial Officer · sold 4,696 at $24.92
$117k
4.6% of stake
Jul 110b5-1 plan
Howard Horn
Chief Financial Officer · sold 4,698 at $33.13
$156k
4.4% of stake
Jun 15No plan
Corazon (corsee) D. Sanders
Director · sold 2,000 at $25.05
$50k
8.7% of stake
Jun 1510b5-1 plan
Karah Herdman Parschauer
EVP and Chief Legal Officer · sold 1,899 at $24.62
$47k
2.0% of stake
Jun 110b5-1 plan
Howard Horn
Chief Financial Officer · sold 4,653 at $23.77
$111k
4.2% of stake
May 1810b5-1 plan
Shehnaaz Suliman
Director · sold 5,740 at $25.12
$144k
17% of stake
May 5No plan
Eric Crombez
EVP and Chief Medical Officer · sold 344 at $24.96
$9k
0.3% of stake
May 110b5-1 plan
Howard Horn
Chief Financial Officer · sold 4,683 at $24.90
$117k
4.1% of stake
Apr 110b5-1 plan
Howard Horn
Chief Financial Officer · sold 4,683 at $20.97
$98k
5.5% of stake
Mar 6 – 10No plan
Karah Herdman Parschauer
EVP and Chief Legal Officer · sold 9,526 at avg $21.87
$208k
12% of stake
Mar 2 – 310b5-1 plan
Howard Horn
Chief Financial Officer · sold 10,044 at avg $22.65
$228k
11% of stake
Mar 2No plan
John Richard Pinion
See Remarks · sold 10,029 at $22.80
$229k
8.4% of stake
Mar 2No plan
Erik Harris
EVP & Chief Commercial Officer · sold 10,539 at $22.80
$240k
11% of stake
Mar 2No plan
Emil D Kakkis
President & CEO · sold 54,404 at $22.80
$1.24M
1.9% of stake
Mar 2No plan
Karah Herdman Parschauer
EVP and Chief Legal Officer · sold 8,135 at $22.80
$185k
9.6% of stake
Mar 2No plan
Theodore Alan Huizenga
SVP, Chief Accounting Officer · sold 1,632 at $22.80
$37k
3.2% of stake
Mar 2No plan
Eric Crombez
EVP and Chief Medical Officer · sold 7,029 at $22.80
$160k
8.4% of stake
Feb 210b5-1 plan
Howard Horn
Chief Financial Officer · sold 3,061 at $23.56
$72k
3.3% of stake
Jan 210b5-1 plan
Howard Horn
Chief Financial Officer · sold 3,150 at $22.84
$72k
3.3% of stake
Dec 29, 2025No plan
Theodore Alan Huizenga
SVP, Chief Accounting Officer · sold 85 at $34.38
$3k
0.2% of stake
Dec 10, 202510b5-1 plan
Howard Horn
Chief Financial Officer · sold 3,081 at $36.38
$112k
3.1% of stake
Oct 13, 2025No plan
Howard Horn
Chief Financial Officer · sold 7,942 at $31.51
$250k
7.5% of stake
Sep 18, 2025No plan
Theodore Alan Huizenga
SVP, Chief Accounting Officer · sold 64 at $29.17
$2k
0.1% of stake
Sep 12, 2025No plan
Karah Herdman Parschauer
EVP and Chief Legal Officer · sold 2,450 at $31.17
$76k
3.2% of stake
Sep 5, 2025No plan
Theodore Alan Huizenga
SVP, Chief Accounting Officer · sold 84 at $31.39
$3k
0.2% of stake
Jun 20, 202510b5-1 plan
Corazon (corsee) D. Sanders
Director · sold 2,405 at $37.39
$90k
14% of stake
Apr 21, 2025 – May 5, 2025No plan
Eric Crombez
EVP and Chief Medical Officer · sold 762 at avg $37.93
$29k
1.1% of stake
Mar 6, 2025No plan
Howard Horn
Chief Financial Officer · sold 1,785 at $40.40
$72k
1.7% of stake
Mar 3, 2025No plan
Thomas Richard Kassberg
CBO & EVP · sold 6,028 at $42.10
$254k
2.2% of stake
Mar 3, 2025No plan
Karah Herdman Parschauer
EVP and Chief Legal Officer · sold 12,846 at $42.10
$541k
15% of stake
Mar 3, 2025No plan
Eric Crombez
EVP and Chief Medical Officer · sold 8,945 at $42.10
$377k
11% of stake
Mar 3, 2025No plan
John Richard Pinion
See Remarks · sold 14,439 at $42.10
$608k
12% of stake
Feb 28, 2025 – Mar 3, 202510b5-1 plan
Emil D Kakkis
President & CEO · sold 98,434 at avg $42.20
$4.15M
3.4% of stake
Mar 3, 2025No plan
Erik Harris
EVP & Chief Commercial Officer · sold 15,103 at $42.10
$636k
15% of stake
Mar 3, 2025No plan
Theodore Alan Huizenga
SVP, Chief Accounting Officer · sold 967 at $42.10
$41k
1.9% of stake
Feb 27, 2025No plan
Karah Herdman Parschauer
EVP and Chief Legal Officer · sold 2,990 at avg $42.88
$128k
4.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RARE, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

BBIOBridgeBio Pharma, Inc.

AMPHAmphastar Pharmaceuticals Inc.

TGTXTG Therapeutics, Inc.

PCRXPacira BioSciences Inc.

KNSAKiniksa Pharmaceuticals International, plc

ARWRArrowhead Pharmaceuticals Inc.

EBSEmergent BioSolutions Inc.

AXSMAxsome Therapeutics, Inc.

Spot a number that looks wrong? Check it in RARE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RARE

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.